DK1104306T3 - Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf - Google Patents

Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf

Info

Publication number
DK1104306T3
DK1104306T3 DK99939711T DK99939711T DK1104306T3 DK 1104306 T3 DK1104306 T3 DK 1104306T3 DK 99939711 T DK99939711 T DK 99939711T DK 99939711 T DK99939711 T DK 99939711T DK 1104306 T3 DK1104306 T3 DK 1104306T3
Authority
DK
Denmark
Prior art keywords
methods
saponin adjuvants
cpg
preparations
immunostimulatory oligonucleotides
Prior art date
Application number
DK99939711T
Other languages
English (en)
Inventor
Charlotte A Kensil
Original Assignee
Antigenics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antigenics Inc filed Critical Antigenics Inc
Application granted granted Critical
Publication of DK1104306T3 publication Critical patent/DK1104306T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
DK99939711T 1998-08-10 1999-08-06 Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf DK1104306T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9591398P 1998-08-10 1998-08-10
US12860899P 1999-04-08 1999-04-08

Publications (1)

Publication Number Publication Date
DK1104306T3 true DK1104306T3 (da) 2006-05-22

Family

ID=26790746

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99939711T DK1104306T3 (da) 1998-08-10 1999-08-06 Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf

Country Status (11)

Country Link
US (2) US7049302B1 (da)
EP (1) EP1104306B1 (da)
JP (1) JP4620251B2 (da)
AT (1) ATE315405T1 (da)
AU (1) AU773204C (da)
CA (1) CA2340174C (da)
DE (1) DE69929444T2 (da)
DK (1) DK1104306T3 (da)
ES (1) ES2257068T3 (da)
PT (1) PT1104306E (da)
WO (1) WO2000009159A1 (da)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US20030026782A1 (en) 1995-02-07 2003-02-06 Arthur M. Krieg Immunomodulatory oligonucleotides
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6589940B1 (en) 1997-06-06 2003-07-08 Dynavax Technologies Corporation Immunostimulatory oligonucleotides, compositions thereof and methods of use thereof
US20020147143A1 (en) 1998-03-18 2002-10-10 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
DK1077722T3 (da) 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
DK1104306T3 (da) * 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
US20030235557A1 (en) 1998-09-30 2003-12-25 Corixa Corporation Compositions and methods for WT1 specific immunotherapy
ATE464907T1 (de) * 1999-02-17 2010-05-15 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
EP2322210A1 (en) * 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
GB9908885D0 (en) * 1999-04-19 1999-06-16 Smithkline Beecham Biolog Vccine
DE60039715D1 (de) * 1999-11-19 2008-09-11 Csl Ltd Hcv-impfstoff zusammensetzungen
WO2001051083A2 (en) * 2000-01-13 2001-07-19 Antigenics Inc. Innate immunity-stimulating compositions of cpg and saponin and methods thereof
AU5615601A (en) 2000-02-23 2001-09-03 Smithkline Beecham Biolog Novel compounds
ATE526994T1 (de) 2000-06-20 2011-10-15 Corixa Corp Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
WO2002000174A2 (en) 2000-06-28 2002-01-03 Corixa Corporation Compositions and methods for the therapy and diagnosis of lung cancer
UA79735C2 (uk) 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
PL208755B1 (pl) * 2000-10-18 2011-06-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
DE60131670T2 (de) * 2000-10-18 2008-10-30 Glaxosmithkline Biologicals S.A. Impfstoffe gegen Krebskrankheiten
WO2002089747A2 (en) 2001-05-09 2002-11-14 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
DE60234375D1 (de) 2001-09-14 2009-12-24 Cytos Biotechnology Ag VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG
AU2002365279B2 (en) 2001-12-17 2009-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
EP1467755A1 (en) * 2001-12-21 2004-10-20 Antigenics Inc. Compositions comprising immunoreactive reagents and saponins, and methods of use thereof
CA2488856A1 (en) * 2002-06-20 2003-12-31 Cytos Biotechnology Ag Packaged virus-like particles for use as adjuvants: method of preparation and use
EP1531858A2 (en) * 2002-07-10 2005-05-25 Akzo Nobel N.V. Immunogenic composition comprising a fusion protein and a saponin adjuvant
JP2006512927A (ja) 2002-12-11 2006-04-20 コーリー ファーマシューティカル グループ，インコーポレイテッド ５’ｃｐｇ核酸およびその使用方法
CA2521050A1 (en) * 2003-04-02 2004-10-14 Coley Pharmaceutical Group, Ltd. Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
US7399467B2 (en) 2003-12-23 2008-07-15 Arbor Vita Corporation Antibodies for oncogenic strains of HPV and methods of their use
WO2005072290A2 (en) * 2004-01-23 2005-08-11 Joslin Diabetes Center Methods of treating, reducing, or preventing autoimmune conditions
AU2005249212B2 (en) 2004-05-28 2010-05-20 Glaxosmithkline Biologicals S.A. Vaccine compositions comprising virosomes and a saponin adjuvant
EP2392349A3 (en) 2005-03-31 2012-01-18 GlaxoSmithKline Biologicals S.A. Vaccines against chlamydial infection
EP2390360A1 (en) 2006-06-02 2011-11-30 GlaxoSmithKline Biologicals S.A. Method for identifying whether a patient will be responder or not to immunotherapy based on the differential expression of the IDO1 gene
WO2008057529A2 (en) * 2006-11-06 2008-05-15 Coley Pharmaceutical Group, Inc. Peptide-based vaccine compositions to endogenous cholesteryl ester transfer protein (cetp)
MX351247B (es) 2007-04-04 2017-10-05 Infectious Disease Res Institute Star Composiciones inmunogenicas que comprenden polipeptidos de mycobacterium tuberculosis y fusiones de los mismos.
US8188058B2 (en) * 2007-04-19 2012-05-29 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists, toll-like receptor-4 antagonists, and/or nuclear oligomerization domain-2 agonists for the treatment or prevention of toll-like receptor-4-associated disorders
US8518903B2 (en) 2007-04-19 2013-08-27 University of Pittsburgh—of the Commonwealth System of Higher Education Use of toll-like receptor-9 agonists
PT2148697E (pt) * 2007-05-24 2012-12-24 Glaxosmithkline Biolog Sa Composição liofilizada de wt-1 contendo cpg
CN101932723B (zh) 2007-09-17 2014-09-10 肿瘤甲基化科学公司 改进的对mage-a表达的检测
RU2510280C2 (ru) 2008-06-27 2014-03-27 Пфайзер Инк. Новые адъювантные композиции
TW201010719A (en) * 2008-08-19 2010-03-16 Wyeth Corp Immunological composition
CN102282155B (zh) 2008-12-02 2017-06-09 日本波涛生命科学公司 磷原子修饰的核酸的合成方法
ES2399218T3 (es) * 2008-12-23 2013-03-26 Intervet International Bv Saponinas inmunoestimulantes para usar en terapia de destrucción tumoral in situ
EP2202298A1 (en) 2008-12-23 2010-06-30 Stichting Dienst Landbouwkundig Onderzoek Recombinant classical swine fever virus (CSFV) comprising a modified E2 protein and methods for generating said recombinant CSFV
EP2408933A2 (en) 2009-03-17 2012-01-25 MDxHealth SA Improved detection of gene expression
IN2012DN00720A (da) 2009-07-06 2015-06-19 Ontorii Inc
GB0917457D0 (en) 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
ES2683316T3 (es) 2010-05-28 2018-09-26 Zoetis Belgium S.A. Vacunas que comprenden colesterol y CpG como únicas moléculas transportadoras de adyuvante
US9072760B2 (en) 2010-09-24 2015-07-07 University of Pittsburgh—of the Commonwealth System of Higher Education TLR4 inhibitors for the treatment of human infectious and inflammatory disorders
DK2620428T3 (da) 2010-09-24 2019-07-01 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
US10668092B2 (en) 2010-09-24 2020-06-02 The John Hopkins University Compositions and methods for treatment of inflammatory disorders
US20130345079A1 (en) 2010-10-27 2013-12-26 Infectious Disease Research Institute Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
WO2012064659A1 (en) 2010-11-08 2012-05-18 Infectious Disease Research Institute Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
WO2012088425A2 (en) 2010-12-22 2012-06-28 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Gap junction-enhancing agents for treatment of necrotizing enterocolitis and inflammatory bowel disease
GB201106357D0 (en) 2011-04-14 2011-06-01 Pessi Antonello Composition and uses thereof
AU2012273153A1 (en) 2011-06-21 2013-05-02 Oncofactor Corporation Compositions and methods for the therapy and diagnosis of cancer
JP6128529B2 (ja) 2011-07-19 2017-05-17 ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． 官能化核酸の合成のための方法
DK2872485T3 (da) 2012-07-13 2021-03-08 Wave Life Sciences Ltd Asymmetrisk hjælpegruppe
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
HRP20240164T1 (hr) 2012-08-03 2024-04-12 Access To Advanced Health Institute Pripravci i postupci za liječenje aktivne tuberkulozne infekcije mikobakterijama
WO2014052453A1 (en) 2012-09-25 2014-04-03 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Oral therapy of necrotizing enterocolitis
ES2728865T3 (es) 2013-03-28 2019-10-29 Infectious Disease Res Inst Vacunas que comprenden polipéptidos de Leishmania para el tratamiento y el diagnóstico de la leishmaniasis
EP3049105B1 (en) 2013-09-19 2020-12-30 Moredun Research Institute Vaccine
JPWO2015108048A1 (ja) * 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
EP3095460A4 (en) * 2014-01-15 2017-08-23 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent
KR20220106232A (ko) 2014-01-16 2022-07-28 웨이브 라이프 사이언시스 리미티드 키랄 디자인
EA201692458A1 (ru) 2014-05-28 2017-06-30 Агенус Инк. Анти-gitr антитела и способы их применения
AR102547A1 (es) 2014-11-07 2017-03-08 Takeda Vaccines Inc Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
AU2015252119A1 (en) 2014-11-07 2016-05-26 Takeda Vaccines, Inc. Hand, foot, and mouth vaccines and methods of manufacture and use thereof
MX2017009306A (es) 2015-01-16 2017-11-08 Zoetis Services Llc Vacuna contra la fiebre aftosa.
WO2016138164A1 (en) * 2015-02-26 2016-09-01 Thevax Genetics Vaccine Co., Ltd. A vaccine composition comprising an immunogenic protein and combination adjuvants for use in eliciting antigen-specific t-cell responses
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc A preparation containing at least two different complexes of purified stress protein linked to an antigenic peptide
EP3302544A4 (en) 2015-05-26 2019-01-09 Ohio State Innovation Foundation NANOPARTICLE-BASED VACCINE STRATEGY AGAINST SWINE INFLUENZA VIRUS
US10456459B2 (en) 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
JP6869987B2 (ja) 2015-09-01 2021-05-12 アジェナス インコーポレイテッド 抗ｐｄ−１抗体及びその使用方法
TWI717432B (zh) 2015-12-02 2021-02-01 美商艾吉納斯公司 抗體和使用彼之方法
JP2019521095A (ja) 2016-05-21 2019-07-25 インフェクシャス ディズィーズ リサーチ インスティチュート 二次性結核および非結核性マイコバクテリウム感染症を治療するための組成物および方法
US10639368B2 (en) 2016-05-27 2020-05-05 Agenus Inc. Anti-TIM-3 antibodies and methods of use thereof
BR112019004913B1 (pt) 2016-09-16 2022-07-12 Infectious Disease Research Institute Vacinas que compreendem polipeptídeos de mycobacterium leprae para a prevenção, tratamento e diagnóstico de lepra
MA46529A (fr) 2016-10-11 2019-08-21 Agenus Inc Anticorps anti-lag-3 et leurs procédés d'utilisation
EP3568412A2 (en) 2017-01-13 2019-11-20 Agenus Inc. T cell receptors that bind to ny-eso-1 and methods of use thereof
MX2019012223A (es) 2017-04-13 2019-12-09 Agenus Inc Anticuerpos anti-cd137 y metodos de uso de los mismos.
FI3618863T3 (fi) 2017-05-01 2023-09-01 Agenus Inc Anti-TIGIT-vasta-aineita ja menetelmiä niiden käyttämiseksi
US11123415B2 (en) 2017-08-16 2021-09-21 Ohio State Innovation Foundation Nanoparticle compositions for Salmonella vaccines
CN107537035A (zh) * 2017-08-30 2018-01-05 北京恩元华生物科技有限公司 复合佐剂及含复合佐剂的狂犬疫苗及其制备方法和应用
AU2018326875A1 (en) 2017-09-04 2020-03-19 Agenus Inc. T cell receptors that bind to mixed lineage leukemia (MLL)-specific phosphopeptides and methods of use thereof
EP3703739A2 (en) 2017-11-03 2020-09-09 Takeda Vaccines, Inc. Zika vaccines and immunogenic compositions, and methods of using the same
AU2019261451A1 (en) 2018-04-26 2020-12-03 Agenus Inc. Heat shock protein-binding peptide compositions and methods of use thereof
GB201901608D0 (en) 2019-02-06 2019-03-27 Vib Vzw Vaccine adjuvant conjugates
CR20220076A (es) 2019-08-30 2022-06-24 Agenus Inc Anticuerpos anti-cd96 y sus métodos de uso
BR112022011445A2 (pt) * 2019-12-13 2022-08-30 Grand Theravac Life Science Nanjing Co Ltd Composição imunoestimuladora e uso da mesma
CN113058033A (zh) * 2019-12-16 2021-07-02 远大赛威信生命科学(南京)有限公司 一种用于预防和治疗乙型肝炎的药物组合物及其用途
CA3188708A1 (en) 2020-08-07 2022-02-10 Access To Advanced Health Institute Purified saponins and chromatographic process for purification of same
WO2022226534A2 (en) * 2021-04-23 2022-10-27 Oakwood Laboratories, Llc Microsphere formulations comprising multiple non-identical peptides and methods for making the same

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US5352449A (en) 1986-05-30 1994-10-04 Cambridge Biotech Corporation Vaccine comprising recombinant feline leukemia antigen and saponin adjuvant
US5583112A (en) 1987-05-29 1996-12-10 Cambridge Biotech Corporation Saponin-antigen conjugates and the use thereof
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
US5650398A (en) 1992-07-02 1997-07-22 Cambridge Biotech Corporation Drug delivery enhancement via modified saponins
US5273965A (en) 1992-07-02 1993-12-28 Cambridge Biotech Corporation Methods for enhancing drug delivery with modified saponins
ES2326118T3 (es) * 1993-09-20 2009-10-01 The Trustees Of The University Of Pennsylvania Regulacion de la expresion del gen bcl-2.
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
US6239116B1 (en) * 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6429199B1 (en) * 1994-07-15 2002-08-06 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
DK0772619T4 (da) * 1994-07-15 2011-02-21 Univ Iowa Res Found Immunmodulatoriske oligonukleotider
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6335018B1 (en) * 1995-05-01 2002-01-01 Aventis Pasteur Limited High molecular weight major outer membrane protein of moraxella
US5968909A (en) * 1995-08-04 1999-10-19 Hybridon, Inc. Method of modulating gene expression with reduced immunostimulatory response
US6231859B1 (en) 1996-12-02 2001-05-15 Aquila Biopharmaceuticals, Inc. Saponin adjuvant compositions
AU738513B2 (en) * 1997-02-28 2001-09-20 University Of Iowa Research Foundation, The Use of nucleic acids containing unmethylated CpG dinucleotide in the treatment of LPS-associated disorders
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
ATE370740T1 (de) * 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
ATE286399T1 (de) 1997-05-20 2005-01-15 Galenica Pharmaceuticals Inc Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung
ATE252596T1 (de) 1997-06-06 2003-11-15 Dynavax Tech Corp Immunstimulierende oligonucleotide, zusammensetzungen davon, und verfahren zur verwendung davon
CA2302522C (en) 1997-08-29 2010-08-17 Aquila Biopharmaceuticals, Inc. Compositions comprising the adjuvant qs-21 and polysorbate or cyclodextrin as excipient
US6013258A (en) * 1997-10-09 2000-01-11 Zycos Inc. Immunogenic peptides from the HPV E7 protein
ATE356630T1 (de) * 1998-04-03 2007-04-15 Univ Iowa Res Found Verfahren und produkte zur stimulierung des immunsystems mittels immunotherapeutischer oligonukleotide und zytokine
DE69927495T2 (de) 1998-05-14 2006-07-06 Coley Pharmaceutical Group, Inc., Wellesley Verfahren zur regulieren der hämatopoese mit hilfe von cpg-oligonukleotiden
DK1077722T3 (da) * 1998-05-22 2006-11-27 Ottawa Health Research Inst Fremgangsmåder og produkter til induktion af mukosaimmunitet
US6562798B1 (en) 1998-06-05 2003-05-13 Dynavax Technologies Corp. Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US20010034330A1 (en) 1998-08-10 2001-10-25 Charlotte Kensil Innate immunity-stimulating compositions of CpG and saponin and methods thereof
DK1104306T3 (da) * 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
EP1117433A1 (en) 1998-10-09 2001-07-25 Dynavax Technologies Corporation Anti hiv compositions comprising immunostimulatory polynucleotides and hiv antigens
EP2322210A1 (en) 1999-04-19 2011-05-18 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
PL208755B1 (pl) 2000-10-18 2011-06-30 Glaxosmithkline Biolog Sa Kompozycja immunogenna oraz zastosowanie połączenia saponiny, oligonukleotydu immunostymulującego i lipopolisacharydu
US20030119774A1 (en) * 2001-09-25 2003-06-26 Marianna Foldvari Compositions and methods for stimulating an immune response
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.
WO2003030934A2 (en) * 2001-10-06 2003-04-17 Merial Limited Cpg formulations and related methods
SE0301998D0 (sv) * 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
GB0401239D0 (en) * 2004-01-21 2004-02-25 Molecularnature Ltd Adjuvant compositions

Also Published As

Publication number Publication date
ES2257068T3 (es) 2006-07-16
PT1104306E (pt) 2006-05-31
DE69929444T2 (de) 2006-09-28
AU773204B2 (en) 2004-05-20
JP2002522510A (ja) 2002-07-23
CA2340174A1 (en) 2000-02-24
AU5395399A (en) 2000-03-06
EP1104306B1 (en) 2006-01-11
EP1104306A1 (en) 2001-06-06
WO2000009159A1 (en) 2000-02-24
WO2000009159A9 (en) 2000-07-27
US7049302B1 (en) 2006-05-23
CA2340174C (en) 2011-01-04
DE69929444D1 (de) 2006-04-06
US7858589B2 (en) 2010-12-28
ATE315405T1 (de) 2006-02-15
AU773204C (en) 2005-05-19
JP4620251B2 (ja) 2011-01-26
US20060177458A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
DK1104306T3 (da) Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
MY125202A (en) Vaccine
EP1594536A4 (en) ADJUVANT INFLUENZA VACCINE
GB0123580D0 (en) Vaccine
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
NO20015073L (no) Vaksiner
PT865297E (pt) Composicoes de vacinas para administracao intranasal compreendendo quitosano e suas utilizacoes
WO2004030608A3 (en) Nanoemulsion vaccines
MXPA01007760A (es) Compuesto adyuvante inmunologico.
AU5162201A (en) Immunostimulant compositions comprising an aminoalkyl glucosaminide phosphate and qs-21
CY1112658T1 (el) Εμβολια τα οποια περιεχουν αντιγονο μαgε συνδεομενο με θραυσμα πρωτεϊνης d
GB2386072A (en) Novel vaccine
MY125000A (en) Novel compositions
ATE392216T1 (de) Mycobakterieller impfstoff
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
AU2002309259A1 (en) Improved polysaccharide and glycoconjugate vaccines_____________
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2000050073A3 (en) Caulobacter lps immunoadjuvant
WO2000006198A3 (en) Adjuvant comprising pulmonary surfactant
DE69922212D1 (de) Impfstoff enthaltend zytokin-induzierte heat shock proteine (hsp)
WO2001015727A3 (en) Compositions of immunostimulatory polymers and saponin adjuvants and uses thereof
DK0952771T3 (da) Hidtil ukendte saponinpræparater og anvendelser deraf
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
MY127452A (en) Vaccines.